Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33385313)
Watch
English
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
title
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
(English)
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
main subject
multicenter clinical trial
0 references
hepatocellular carcinoma
1 reference
based on heuristic
inferred from title
author
Ana Ruiz-Garcia
object named as
Ana Ruiz-Garcia
series ordinal
12
0 references
Sandrine Faivre
object named as
Sandrine Faivre
series ordinal
1
0 references
Jean-Yves Douillard
series ordinal
4
object named as
Jean Douillard
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Ann-Lii Cheng
1 reference
stated in
ORCID Public Data File 2021
author name string
Eric Raymond
series ordinal
2
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Eveline Boucher
series ordinal
3
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Ho Y Lim
series ordinal
5
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Jun S Kim
series ordinal
6
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Magaly Zappa
series ordinal
7
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Silvana Lanzalone
series ordinal
8
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Xun Lin
series ordinal
9
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Samuel Deprimo
series ordinal
10
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Charles Harmon
series ordinal
11
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Maria J Lechuga
series ordinal
13
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Ann Lii Cheng
series ordinal
14
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
publication date
6 July 2009
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
published in
Lancet Oncology Commission
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
volume
10
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
page(s)
794-800
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
issue
8
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
cites work
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Global cancer statistics, 2002
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
International trends and patterns of primary liver cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Design and endpoints of clinical trials in hepatocellular carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tumor-induced lymphangiogenesis: a target for cancer therapy?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorafenib in advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular basis for sunitinib efficacy and future clinical development
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Management of hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970171-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(09)70171-8
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
PubMed ID
19586800
1 reference
stated in
Q5412157
PubMed ID
19586800
retrieved
26 July 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
